The FDA has extended its review of Belite Bio’s experimental eye disease drug tinlarebant by three months, moving its decision deadline to May 12, 2027.
The agency needs additional time to evaluate information supporting the drug’s application for Stargardt disease type 1, an inherited retinal disorder, according to a Nov. 20 news release.
If the FDA identifies no major deficiencies during its ongoing review, it plans to communicate proposed labeling changes and any anticipated postmarketing requirements by April 12, 2027.
Tinlarebant is an oral treatment designed to slow the buildup of vitamin A-related toxins that contribute to retinal damage. The drug met its primary endpoint in Belite Bio’s completed phase 3 DRAGON trial involving adolescents and adults with Stargardt disease type 1.
Belite Bio is also evaluating tinlarebant in a phase 2/3 trial for Stargardt disease and a separate phase 3 trial for geographic atrophy, an advanced form of dry age-related macular degeneration.